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BACKGROUND
Transthyretin amyloid cardiomyopathy is caused by the deposition of transthyretin amy-
loid fibrils in the myocardium. The deposition occurs when wild-type or variant trans-
thyretin becomes unstable and misfolds. Tafamidis binds to transthyretin, preventing 
tetramer dissociation and amyloidogenesis.
METHODS
In a multicenter, international, double-blind, placebo-controlled, phase 3 trial, we 
randomly assigned 441 patients with transthyretin amyloid cardiomyopathy in a 2:1:2 
ratio to receive 80 mg of tafamidis, 20 mg of tafamidis, or placebo for 30 months. 
In the primary analysis, we hierarchically assessed all-cause mortality, followed by 
frequency of cardiovascular-related hospitalizations according to the Finkelstein–
Schoenfeld method. Key secondary end points were the change from baseline to 
month 30 for the 6-minute walk test and the score on the Kansas City Cardiomyopathy 
Questionnaire–Overall Summary (KCCQ-OS), in which higher scores indicate better 
health status.
RESULTS
In the primary analysis, all-cause mortality and rates of cardiovascular-related hos-
pitalizations were lower among the 264 patients who received tafamidis than among 
the 177 patients who received placebo (P<0.001). Tafamidis was associated with lower 
all-cause mortality than placebo (78 of 264 [29.5%] vs. 76 of 177 [42.9%]; hazard ratio, 
0.70; 95% confidence interval [CI], 0.51 to 0.96) and a lower rate of cardiovascular-
related hospitalizations, with a relative risk ratio of 0.68 (0.48 per year vs. 0.70 per year; 
95% CI, 0.56 to 0.81). At month 30, tafamidis was also associated with a lower rate of 
decline in distance for the 6-minute walk test (P<0.001) and a lower rate of decline 
in KCCQ-OS score (P<0.001). The incidence and types of adverse events were similar 
in the two groups.
CONCLUSIONS
In patients with transthyretin amyloid cardiomyopathy, tafamidis was associated 
with reductions in all-cause mortality and cardiovascular-related hospitalizations 
and reduced the decline in functional capacity and quality of life as compared with 
placebo. (Funded by Pfizer; ATTR-ACT ClinicalTrials.gov number, NCT01994889.)
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Transthyretin amyloid cardiomy­opathy is a life-threatening disease charac-terized by the accumulation of amyloid fi-
brils composed of misfolded transthyretin protein 
in the heart.1 Misfolded monomers or oligomers 
of transthyretin are deposited in the myocardium, 
leading to cardiomyopathy and symptoms of heart 
failure, including dyspnea, fatigue, orthostatic hy-
potension, and syncope.2 Infiltration of the con-
duction system can lead to bundle-branch block, 
atrioventricular block, sinoatrial disease, and atrial 
fibrillation.
Transthyretin amyloid cardiomyopathy is a late-
onset disease; symptoms are predominately mani-
fested in male patients 60 years of age or older.2 
The condition can be inherited as an autosomal 
dominant trait caused by pathogenic mutations 
in the transthyretin gene TTR (ATTRm) or by the 
deposition of wild-type transthyretin protein 
(ATTRwt), previously called senile systemic amy-
loidosis.3 There are more than 120 pathogenic 
mutations in TTR that result in a variable pheno-
typic presentation.2,3 Although the prevalence of 
ATTRwt is uncertain, studies that use an approach 
to diagnosis that is not based on biopsy4,5 have 
reported a prevalence of 13% among patients with 
heart failure with a preserved ejection fraction,6 
16% among patients undergoing transcatheter 
aortic-valve replacement for severe aortic steno-
sis,7 and 5% among patients with presumed hy-
pertrophic cardiomyopathy.8 Treatments have been 
limited to supportive care, with no guideline-rec-
ommended treatment. Median survival in untreat-
ed patients is reported to be 2.5 years after diag-
nosis for ATTRm caused by the TTR Val122Ile 
mutation and 3.6 years for ATTRwt.9,10 Death in 
most patients is from cardiac causes, including 
sudden death and heart failure.9
Transthyretin is a 127-amino acid, 55-kD pro-
tein that is primarily synthesized in the liver and 
transports thyroxine and retinol-binding protein-
retinol (vitamin A) complex.11,12 Fibrillogenesis oc-
curs when the tetrameric structure of the trans-
thyretin protein dissociates into intermediates, 
which misassemble into soluble oligomers, 
protofilaments, and amyloid fibrils.13 Kelly and 
colleagues discovered that a polymorphism in 
TTR that encodes the amino-acid substitution 
Thr119Met stabilized the protein in the context 
of a destabilizing pathogenic variant (Val30Met), 
leading to the development of tafamidis,14,15 a 
benzoxazole derivative lacking nonsteroidal anti-
inflammatory drug activity that binds to the thy-
roxine-binding sites of transthyretin with high af-
finity and selectivity and inhibits the dissociation 
of tetramers into monomers. Tafamidis has been 
shown to slow the progression of peripheral neu-
rologic impairment in transthyretin amyloid poly-
neuropathy.16
With respect to transthyretin amyloid cardio-
myopathy, a phase 2, open-label trial involving 
31 patients showed that tafamidis (20 mg daily) 
stabilized transthyretin and had an acceptable 
safety profile.17 A single-center, nonrandomized 
study showed an association between tafamidis 
and improved survival.18 The Transthyretin Amyloi-
dosis Cardiomyopathy Clinical Trial (ATTR-ACT)19 
was designed to determine the efficacy and safety 
of tafamidis in patients with hereditary and wild-
type transthyretin amyloid cardiomyopathy.
Me thods
Trial Oversight
ATTR-ACT was a phase 3, multicenter, interna-
tional, parallel-design, placebo-controlled, double-
blind, randomized trial. Details of the trial have 
been described previously.19 The trial was over-
seen by a steering committee that included inves-
tigators and the sponsor. ATTR-ACT was approved 
by the independent review board or ethics com-
mittee at each participating site and was con-
ducted in accordance with the provisions of the 
Declaration of Helsinki and the International 
Conference on Harmonisation Good Clinical Prac-
tice guidelines. All patients provided written in-
formed consent. The trial was designed by the 
sponsor in collaboration with clinicians with expe-
rience in the treatment of transthyretin amyloid 
cardiomyopathy. Investigators collected and held 
the data in a blinded fashion until the data were 
analyzed centrally by the sponsor. An external 
data and safety monitoring board was responsi-
ble for monitoring patient safety and conducted 
unblinded reviews of cumulative trial data. An 
independent, end-point adjudication committee, 
whose members were also unaware of the trial-
group assignments, determined whether investi-
gator-reported events met the definition of dis-
ease-related efficacy end points with the use of 
predefined end-point criteria, thereby maintain-
ing the scientific integrity of the trial. The sta-
tistical analysis was performed by the sponsor, 
and data tables were provided to the investiga-
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tors. All authors participated in the interpreta-
tion of the data and vouch for the accuracy and 
completeness of the data and for the fidelity of 
the trial to the protocol, available with the full 
text of this article at NEJM.org. The first author 
wrote the first draft. All authors participated in 
manuscript development and made the decision 
to publish the results. Agreements between the 
sponsor of the trial, Pfizer, and the investigators 
included data confidentiality.
Patients
Patients between 18 and 90 years of age were 
eligible to participate in ATTR-ACT if they had 
transthyretin amyloid cardiomyopathy (ATTRwt 
or ATTRm) confirmed by the presence of amyloid 
deposits on analysis of biopsy specimens obtained 
from cardiac and noncardiac sites (e.g., fat aspi-
rate, gastrointestinal sites, salivary glands, or 
bone marrow) and, in patients without ATTRm, 
by the presence of transthyretin precursor pro-
tein confirmed on immunohistochemical analy-
sis, scintigraphy, or mass spectrometry. Cardiac 
involvement was confirmed by means of echocar-
diography, with an end-diastolic interventricular 
septal wall thickness exceeding 12 mm; a history 
of heart failure, with at least one prior hospital-
ization for heart failure or clinical evidence of 
heart failure (without hospitalization) manifested 
in signs or symptoms of volume overload or ele-
vated intracardiac pressures requiring treatment 
with a diuretic for improvement; an N-terminal 
pro-B-type natriuretic peptide (NT-proBNP) level 
greater than or equal to 600 pg per milliliter; and 
a 6-minute walk-test distance exceeding 100 m.
Patients were excluded if any one of the fol-
lowing criteria was met: they had, in the opinion 
of the investigator, heart failure that was not due 
to transthyretin amyloid cardiomyopathy; New 
York Heart Association (NYHA) class IV heart 
failure; the presence of light-chain amyloidosis; 
a history of liver or heart transplantation; an im-
planted cardiac device; previous treatment with 
tafamidis; an estimated glomerular filtration rate 
lower than 25 ml per minute per 1.73 m2 of body-
surface area; or liver transaminase levels exceed-
ing two times the upper limit of the normal range. 
Patients were also excluded if they had severe 
malnutrition as defined by a modified body-mass 
index (mBMI) of less than 600, calculated as the 
serum albumin level in grams per liter multiplied 
by the conventional BMI (the weight in kilograms 
divided by the square of the height in meters), or 
were receiving concurrent treatment with non-
steroidal antiinflammatory drugs, tauroursode-
oxycholate, doxycycline, calcium-channel block-
ers, or digitalis.
Trial Design
Patients were randomly assigned to receive 80 mg 
of tafamidis, 20 mg of tafamidis, or matching 
placebo once daily in ratio of a 2:1:2. Stratifica-
tion was conducted according to TTR status (vari-
ant or wild type) and baseline NYHA class. An 
interactive Web-response system was used. The 
trial duration was 30 months, and on completion 
patients were offered enrollment in an extension 
study. Patients who had adverse events that may 
have been associated with treatment and may have 
affected adherence to the dosing regimen or con-
tinued participation in the trial were given the 
option to receive a reduced dose (patients receiving 
a dose of 80 mg would instead receive a dose of 
40 mg, and all others continued to receive the dose 
assigned at randomization).
Analysis Populations
The modified intention-to-treat analysis included 
all patients who were enrolled, received at least 
one dose of tafamidis or placebo, with both pa-
tient and investigator unaware of group assign-
ment, and underwent at least one postbaseline 
efficacy evaluation (i.e., postbaseline hospital-
ization, study visit, or death). The safety analysis 
set included all enrolled patients who received at 
least one dose of tafamidis or placebo. Because 
all patients who were enrolled also fulfilled the 
three other criteria of the modified intention-to-
treat analysis, this analysis was effectively also an 
intention-to-treat analysis.
Outcomes
We hierarchically assessed all-cause mortality, 
followed by frequency of cardiovascular-related 
hospitalizations over the course of the 30-month 
trial. This analysis compared the results of a 
pooled tafamidis (80 mg and 20 mg) treatment 
group with the placebo group. Key secondary end 
points were change from baseline to month 30 in 
both distance walked on the 6-minute walk test,20 
a measure of functional capacity, and the Kansas 
City Cardiomyopathy Questionnaire–Overall Sum-
mary (KCCQ-OS) score,21 which assesses quality 
of life. Scores range from 0 to 100, with lower 
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scores denoting poorer quality of life. Vital status 
at month 30 was assessed for all enrolled patients.
Statistical Analysis
A sample size of 400 patients was estimated to 
give the trial power of at least 90% to detect a 
30% reduction in mortality, a reduction in the 
frequency of cardiovascular-related hospitaliza-
tions from 2.5 to 1.5 (over the 30-month dura-
tion of the trial), or both given treatment with 
tafamidis. Our trial population was targeted to 
comprise at least 30% of patients with ATTRm 
and at least 30% with ATTRwt. Comparisons were 
based on the pooled tafamidis treatment groups of 
80 mg and 20 mg versus placebo, except for spe-
cific dose comparisons. In the primary analysis, 
we hierarchically assessed all-cause mortality, fol-
lowed by frequency of cardiovascular-related hos-
pitalizations with the use of the Finkelstein–
Schoenfeld method,22 which is based on the 
principle that each patient in the clinical trial is 
compared with every other patient within each 
stratum in a pairwise manner. This method 
gives a higher importance to all-cause mortality. 
The pairwise comparison proceeds in hierarchi-
cal fashion, using all-cause mortality, followed by 
frequency of cardiovascular-related hospitaliza-
tion when patients cannot be differentiated on 
the basis of mortality. In the analysis of fre-
quency of cardiovascular-related hospitalization, 
when two patients had different follow-up times, 
the shorter follow-up time was used in compar-
Figure 1. Randomization, Evaluation, and Outcomes.
The most common reasons that screened patients were not admitted to the trial were as follows: closure of enroll-
ment (for patients with wild-type transthyretin protein), N-terminal pro-B-type natriuretic peptide level less than 
600 pg per milliliter, clinical instability, and an estimated glomerular filtration rate lower than 25 ml per minute per 
1.73 m2 of body-surface area. Among patients assigned to receive tafamidis who did not complete the trial, 25 were 
no longer willing to participate, 17 had adverse events, 6 underwent organ transplantation, 2 had implantation of a 
cardiac mechanical assist device (CMAD), 1 was lost to follow-up, and 1 had a protocol violation. Among patients 
assigned to receive placebo, 37 were no longer willing to participate, 11 had an adverse event, 5 underwent organ 
transplantation, and 1 had a protocol violation. Vital status at 30 months was available and confirmed for all pa-
tients who underwent randomization. The numbers shown do not depict the death count for the purpose of pri-
mary analysis. Some reasons for discontinuation (i.e., heart transplantation and CMAD implantation) were treated 
as death in the primary analysis. The total number of actual deaths was 144.
441 Underwent randomization
548 Patients were screened
107 Were excluded
94 Were not eligible
13 Withdrew consent
264 Were assigned to pooled tafamidis
and had efficacy assessment
(intention-to-treat analysis)
177 Were assigned to placebo
and had efficacy assessment
(intention-to-treat analysis)
52 Discontinued study
30-mo vital status:
33 Died
19 Were alive
39 Died during the study
54 Discontinued study 
30-mo vital status:
34 Died
20 Were alive
38 Died during the study
173 Completed the study 85 Completed the study
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITA STUDI DI FIRENZE on October 9, 2018. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med 379;11 nejm.org September 13, 2018 1011
Tafamidis for Tr ansthyretin Amyloid Cardiomyopathy
ing the frequency of their cardiovascular-related 
hospitalizations.
We applied the Finkelstein–Schoenfeld method 
to the patients stratified according to NYHA class 
at baseline (class I or II vs. class III) and TTR 
status (variant vs. wild-type), yielding four strati-
fication pools. Heart transplantation, heart and 
liver transplantation, and implantation of a me-
chanical cardiac-assist device were treated as death 
for the purposes of this analysis. Only one pa-
tient underwent liver transplantation alone, and 
this event was not treated as a death. All-cause 
mortality was analyzed with the use of a Cox 
proportional-hazards model, with treatment and 
the stratification factors treated as covariates.
We compared the frequency of cardiovascular-
related hospitalizations with the use of a Poisson 
regression model, with treatment, TTR status (vari-
ant and wild type), NYHA baseline class (NYHA 
classes I and II combined vs. NYHA class III), 
treatment-by-TTR status interaction, and treat-
ment-by-NYHA baseline class interaction terms as 
factors, with adjustment for treatment duration. 
The key secondary end points were assessed with 
the use of a mixed-effect model, repeated-mea-
sure approach and analysis of covariance,23 with 
an unstructured covariance matrix. Center and 
patient-within-center were treated as random ef-
fects, and treatment, visit, TTR status (ATTRm 
vs. ATTRwt), and visit-by-treatment interaction 
were treated as fixed effects, with the baseline 
value as covariate. A prespecified hierarchical 
testing order (the 6-minute walk test, followed 
by the KCCQ-OS) provided multiplicity protec-
tion against type 1 error. The remaining second-
ary and exploratory analyses and end points were 
not adjusted for multiplicity.
R esult s
Patient Characteristics
From December 2013 through August 2015, a total 
of 548 patients were screened and 441 patients 
enrolled at 48 sites in 13 countries; 264 patients 
received tafamidis (80 mg or 20 mg) and 177 pa-
tients received placebo (Fig. 1; and Table S1 in the 
Supplementary Appendix, available at NEJM.org.). 
Overall, baseline characteristics in the two groups 
were balanced (Table 1, and Table S2 in the Sup-
plementary Appendix). The median age was 75 
years, and patients were predominately male. 
Characteristic
Tafamidis 
(N=264)
Placebo 
(N=177)
Age — yr
Mean 74.5±7.2 74.1±6.7
Median (range) 75 (46–88) 74 (51–89)
Sex — no. (%)
Male 241 (91.3) 157 (88.7)
Female 23 (8.7) 20 (11.3)
Race — no. (%)
White 211 (79.9) 146 (82.5)
Black 37 (14.0) 26 (14.7)
Asian 13 (4.9) 5 (2.8)
Other 3 (1.1) 0
TTR genotype — no. (%)
ATTRm 63 (23.9) 43 (24.3)
ATTRwt 201 (76.1) 134 (75.7)
Blood pressure — mm Hg
Supine
Systolic 115.4±15.4 115.1±15.7
Diastolic 70.4±10.3 70.2±9.5
Standing
Systolic 115.5±15.5 115.9±15.9
Diastolic 70.6±9.9 71.0±10.3
Heart rate, mean — beats per 
minute
Supine 70.7±12.3 69.9±11.7
Standing 72.9±12.9 73.8±12.2
NYHA Class — no. (%)
Class I 24 (9.1) 13 (7.3)
Class II 162 (61.4) 101 (57.1)
Class III 78 (29.5) 63 (35.6)
Modified BMI† 1058.8±173.8 1066.4±194.4
NT-proBNP level — pg/ml
Median 2995.9 3161.0
Interquartile range 1751.5–4861.5 1864.4–4825.0
*  Plus–minus values are means ±SD. There were 264 patients in the tafamidis 
group and 177 patients in the placebo group in both the intention-to-treat and 
safety analyses. Percentages may not total 100 because of rounding. NT-
proBNP denotes N-terminal pro-B-type natriuretic peptide, and NYHA New 
York Heart Association.
†  The modified body-mass index (BMI) is calculated as the serum albumin level 
in grams per liter multiplied by the conventional BMI (the weight in kilograms 
divided by the square of the height in meters).
Table 1. Demographic and Clinical Characteristics of the Patients  
at Baseline.*
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Among those who underwent randomization, 
106 (24%) had ATTRm with Val122Ile, Thr60Ala, 
and Ile68Leu being the most common mutations. 
Predefined treatment adherence (taking ≥80% of 
scheduled doses) was high, at 97.2% for tafam-
idis and 97.0% for placebo.
Efficacy
In the primary analysis that hierarchically assessed 
all-cause mortality, followed by frequency of car-
diovascular-related hospitalization, according to 
analyses performed with the Finkelstein–Schoen-
feld method, treatment with tafamidis was supe-
rior to placebo over 30 months (P<0.001). The 
win ratio24 (number of pairs of treated-patient 
“wins” divided by number of pairs of placebo-
patient “wins”) may be helpful in interpreting 
the Finkelstein–Schoenfeld result. The win ratio 
is 1.695 (95% confidence interval [CI], 1.255 to 
2.289). According to Cox regression analysis, all-
cause mortality was lower with tafamidis than 
with placebo (78 of 264 [29.5%] vs. 76 of 177 
Figure 2. Primary Analysis and Components.
Panel A shows the results of the primary analysis as determined with the use of the Finkelstein–Schoenfeld method. 
Panel B shows an analysis of all-cause mortality for pooled tafamidis and for placebo, a secondary end point. Panel 
C shows the frequency of cardiovascular-related hospitalizations, also a secondary end point.
B Analysis of All-Cause Mortality
C Frequency of Cardiovascular-Related Hospitalizations
A Primary Analysis, with Finkelstein–Schoenfeld Method
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[42.9%]; hazard ratio, 0.70; 95% CI, 0.51 to 0.96). 
According to the Poisson regression analysis, the 
rate of cardiovascular-related hospitalizations 
(0.48 vs. 0.70 hospitalizations per year; relative 
risk ratio, 0.68; 95% CI, 0.56 to 0.81) was lower 
with tafamidis than with placebo (see Table S3 
in the Supplementary Appendix for post hoc 
negative binomial analysis). Kaplan–Meier sur-
vival curves showed that tafamidis resulted in a 
reduction in all-cause mortality, with the curves 
diverging after approximately 18 months of treat-
ment (Fig. 2). Across prespecified subgroups, in-
cluding those based on TTR status (ATTRwt vs. 
ATTRm), NYHA class (I or II vs. III), and tafam-
idis dose (80 mg vs. 20 mg), the difference in 
all-cause mortality and frequency of cardiovas-
cular-related hospitalizations favored tafamidis 
over placebo, except in patients with NYHA class 
III disease at baseline, among whom the rates of 
cardiovascular-related hospitalizations were high-
er among patients receiving tafamidis than among 
those receiving placebo (Fig. 3). Using a prespeci-
fied Poisson-regression analysis, we observed an 
interaction between treatment and NYHA base-
line classification. We did not observe an inter-
action between treatment and TTR status. A pre-
specified sensitivity analysis of all-cause mortality 
that did not treat transplantation involving heart 
transplantation or implantation of a cardiac me-
chanical assist device as death yielded a hazard 
ratio of 0.67 (95% CI, 0.49 to 0.94). An additional 
post hoc analysis of time to first cardiovascular-
related hospitalization is provided (see Fig. S1 in 
the Supplementary Appendix).
Key secondary end points included the change 
from baseline to month 30 in the distance walked 
during the 6-minute walk test and in KCCQ-OS 
score. Tafamidis reduced the decline in the dis-
tance walked during the 6-minute test as com-
pared with placebo (75.68 m [standard error, ±9.24; 
P<0.001]), with differences first observed at 
month 6 (Fig. 4A). Tafamidis also reduced the 
decline in the KCCQ-OS score as compared with 
placebo (13.65 [standard error, ±2.13; P<0.001]), 
with differences first observed at month 6 (Fig. 4B).
Exploratory end points included a smaller in-
crease in the NT-proBNP level among patients 
receiving tafamidis than among those receiving 
placebo at months 12 and 30 (least-squares mean 
difference, −735.14 [95% CI, −1249.16 to −221.13] 
at 12 months and −2180.54 [95% CI, −3326.14 to 
−1034.95] at 30 months). Directionally positive 
echocardiographic findings (see Table S4 in the 
Supplementary Appendix), including a smaller de-
Figure 3. Overall and Subgroup Results as Calculated with the Use of the Finkelstein–Schoenfeld Method, All-Cause Mortality,  
and Cardiovascular-Related Hospitalizations.
All-cause mortality was evaluated with the use of a Cox proportional-hazards model, with treatment and stratification factors treated as 
covariates. The survival analysis interaction terms are based on a post hoc analysis. The frequency of cardiovascular-related hospitaliza-
tions was assessed with the use of a Poisson regression model. ATTRm denotes disease that results from an inherited autosomal domi-
nant trait that is caused by pathogenic mutations in TTR, ATTRwt disease that results from the deposition of wild-type transthyretin 
protein, and NYHA New York Heart Association.
0.50 1.00 2.00
Placebo BetterTafamidis Better
Overall — pooled tafamidis
 vs. placebo
TTR genotype
ATTRm
ATTRwt
NYHA baseline
Class I or II
Class III
Dose
80 mg vs. placebo
20 mg vs. placebo
Cardiovascular Hospitalization
Relative Risk Ratio (95% CI)
P Value from
Finkelstein–
Schoenfeld
Method
Survival Analysis
Hazard Ratio (95% CI)Subgroup
0.25
P Value for
Interaction
<0.001
0.30  
<0.001
<0.001
0.78  
0.003
0.005
P Value for
Interaction
0.79
0.22
0.11  
<0.001
0.50 1.00 2.00
Placebo BetterTafamidis Better
0.25
 
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITA STUDI DI FIRENZE on October 9, 2018. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med 379;11 nejm.org September 13, 20181014
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
crease in left ventricular stroke volume (least-
squares mean difference, 6.28), were noted at 
month 30.
Safety and Adverse Effects
The safety profiles of tafamidis and placebo were 
similar. There was no meaningful difference in 
the safety of the two doses of tafamidis. Adverse 
events that emerged during treatment were gen-
erally mild to moderate in severity, and perma-
nent discontinuation of tafamidis or placebo as 
a result of adverse events was less common in 
the tafamidis groups than in the placebo group 
(Table S5 in the Supplementary Appendix). Dose 
reduction related to adverse events were uncom-
mon (two patients receiving tafamidis [0.8%] and 
four patients receiving placebo [2.3%]). The results 
of laboratory analyses related to safety did not 
differ between the tafamidis and placebo groups. 
Both diarrhea and urinary tract infections, ad-
verse events previously reported in patients with 
familial amyloid polyneuropathy,25 were less com-
mon in patients who received tafamidis than in 
those who received placebo. The most frequent 
adverse events are summarized in the Supplemen-
tary Appendix.
Discussion
ATTR-ACT showed that tafamidis is superior to 
placebo in reducing the combination of all-cause 
mortality and cardiovascular-related hospitaliza-
tions. The evidence also supports the assertion 
that the risk of each component, when analyzed 
independently of the other, is reduced. Tafamidis 
was also associated with a significant reduction 
in the decline in functional capacity (as measured 
by the 6-minute walk test) and the decline in 
quality of life (as measured by the KCCQ-OS) at 
month 30, with differences first observed at 
6 months. In contrast, the effect on overall sur-
vival emerged after approximately 18 months. This 
dissociation between the effect on symptoms and 
survival has also been observed with other thera-
pies for systolic heart failure in which ventricular 
remodeling takes months to achieve.26-28
We observed a consistent benefit from tafam-
idis related to mortality across all subgroups. We 
also observed fewer cardiovascular-related hos-
pitalizations among those who received tafamidis 
across all subgroups, with the exception of those 
with NYHA class III. We speculate that the high-
er hospitalization rate observed in this group is 
attributable to longer survival during a more 
severe period of disease, underscoring the im-
portance of early diagnosis and treatment of this 
fatal, progressive disease, which can be difficult 
to diagnose.29 Given the progressive nature of the 
disease and the mechanism through which tafam-
idis reduces amyloidogenesis — by specifically 
Figure 4. Key Secondary End Points.
Panel A shows the least-squares (LS) mean (±SE) change from baseline  
to month 30 in the distance walked in the 6-minute walk test in the pooled 
tafamidis group as compared with the placebo group. Panel B shows the 
LS mean (±SE) change from baseline for both groups in the Kansas City 
Cardiomyopathy Questionnaire–Overall Summary (KCCQ-OS) score, in 
which higher scores indicate better health status. I bars indicated standard 
errors.
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stabilizing transthyretin tetramers — the drug is 
expected to have greater benefit when adminis-
tered early in the disease course.30
When the trial was designed, tissue biopsy 
was required for diagnosis, but an approach 
without biopsy — in which technetium-labeled 
bone scintigraphy tracing is used instead — has 
been validated as a method for the identification 
of patients. This approach is highly sensitive and 
specific for the diagnosis of transthyretin amy-
loid cardiomyopathy4,5,31 and can detect amyloid 
deposits before an increase in left ventricular 
wall thickness or the clinical syndrome of heart 
failure and a rise in cardiac biomarkers has oc-
curred.32,33 This method can even predict prog-
nosis.5,34 Early identification and treatment are 
now more likely given the availability of effective 
diagnostic tools and therapy.
Similarly, innovative methods are being de-
veloped and used for research in rare disease. In 
studies of rare disease such as transthyretin amy-
loid cardiomyopathy, small patient populations 
often limit recruitment and hinder the conduct of 
randomized trials. The Finkelstein–Schoenfeld 
method, used in this trial, is a validated technique 
that increases the sensitivity and power of the 
analysis of smaller cohorts and prioritizes the 
importance of mortality while also addressing 
morbidity.
The overall incidence and type of adverse 
events were similar in the tafamidis and placebo 
groups. Discontinuation of the trial drug owing 
to adverse events that occurred during treatment 
was less common in patients who received ta-
famidis than in those who received placebo, and 
dose reductions were uncommon and occurred 
more often in the placebo group.
In conclusion, in patients with heart failure 
due to transthyretin amyloid cardiomyopathy, 
treatment with tafamidis reduced all-cause mor-
tality and cardiovascular-related hospitalizations 
as compared with placebo. Tafamidis treatment 
also significantly reduced the decline in func-
tional capacity and quality of life. These find-
ings indicate that tafamidis is an effective therapy 
for patients with transthyretin amyloid cardio-
myopathy.
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